Home › Companies › COHERUS BIOSCIENCES INC. › 2024-2025

COHERUS BIOSCIENCES INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and COHERUS BIOSCIENCES INC.’s Form 8-K, filed 2025-06-13 (Item 5.07 on EDGAR). Page generated 04 October 2026.

7Reported items
118Asset managers
858Fund votes
2025-06-11Main meeting date

Proxy season: 2023-2024 2024-2025

Explore COHERUS BIOSCIENCES INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by COHERUS BIOSCIENCES INC.

These tallies are COHERUS BIOSCIENCES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-13 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

COHERUS BIOSCIENCES INC. — official shareholder meeting results, meeting held 2025-06-11
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Jill O'Donnell-Tormey, Ph.D.	32,769,503	--	--	6,158,468	36,656,283	Majority: yes
Elect Director: Michael Ryan	32,735,184	--	--	6,192,787	36,656,283	Majority: yes
Elect Director: Ali J. Satvat	27,759,763	--	--	11,168,208	36,656,283	Majority: yes
Proposal 2. The Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.	74,500,950	776,953	306,351	--	0	Majority: yes
Proposal 3. The Company's stockholders approved a non-binding, advisory resolution to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote).	19,179,927	16,164,644	3,583,400	--	36,656,283	Majority: yes
Proposal 4. The Company's stockholders approved the amendment to the Company's 2014 Employee Stock Purchase Plan (the "ESPP Amendment").	27,741,397	7,585,461	3,601,113	--	36,656,283	Majority: yes

Source: COHERUS BIOSCIENCES INC., Form 8-K, filed with the SEC on 2025-06-13 — read the filing on EDGAR.

How asset managers voted at the COHERUS BIOSCIENCES INC. 2024-2025 meetings

Each item below shows how the 118 asset managers that disclosed a COHERUS BIOSCIENCES INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of COHERUS BIOSCIENCES INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To vote on a non-binding, advisory basis to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote).

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2025-06-11.

Combines 12 wordings of this item as funds reported it.

54.3% Majority: yes · of votes cast

FOR 54.3%AGAINST 45.7%

FOR: 19,179,927AGAINST: 16,164,644

COHERUS BIOSCIENCES INC.’s own tally for this item (“Proposal 3. The Company's stockholders approved a non-binding, advisory resolution to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote).”): 19,179,927 for, 16,164,644 against, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 114,725,740 outstanding shares: 17% for, 14% against (31% of the company cast a for/against vote).

The 115 asset managers below cast 42% of the shares they voted on this item FOR (9,944,185 for, 13,908,655 against).

FOR 42%AGAINST 58%

FOR: 9,944,185 (41.6%)AGAINST: 13,908,655 (58.2%)ABSTAIN: 29,534 (0.1%)NOT VOTED: 13,000 (0.1%)

Largest asset managers voting on “To vote on a non-binding, advisory basis to approve the compensation of the Company's named executive officers” at COHERUS BIOSCIENCES INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	3,299,408	33,039	For
BlackRock	2,753,752	0	For
Rubric Capital Management LP	0	2,550,341	Against
Kohlberg Kravis Roberts & Co. L.P.	2,055,055	0	For
Charles Schwab	0	1,972,394	Against
C WorldWide Asset Management Fondsmaeglerselskab A/S	0	1,928,464	Against
SEI	0	1,715,019	Against
State Street	1,072,248	5,705	For
Delaware/Macquarie	0	900,000	Against
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	0	900,000	Against
Stonepine Capital Management, LLC	0	655,000	Against
Northern Trust	0	542,863	Against
AQR	0	542,517	Against
STRS OHIO	0	324,000	Against
MELLON INVESTMENTS Corp	238,788	0	For
GEODE CAPITAL MANAGEMENT, LLC	0	236,102	Against
Equitable	22,008	188,410	Against
Fidelity	26,015	177,047	Against
AllianceBernstein	0	188,410	Against
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM	0	101,584	Against
Goldman Sachs	0	96,991	Against
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0	91,117	Against
BRIDGEWAY FUNDS INC	0	91,117	Against
Lincoln Financial	83,905	0	For
WisdomTree	80,178	0	For

Showing the 25 largest of 115 asset managers. See all 115 in the interactive database.

2. To elect three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Ali J. Satvat

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-11.

Combines 3 wordings of this item as funds reported it.

71% Majority: yes · of votes cast

FOR 71%WITHHELD 29%

FOR: 27,759,763WITHHELD: 11,168,208

COHERUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Ali J. Satvat”): 27,759,763 for, 11,168,208 withheld, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 114,725,740 outstanding shares: 24% for, 10% withheld (34% of the company cast a for/withheld vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (5,581,345 for, 0 against).

FOR 71%ABSTAIN 29%

FOR: 5,581,345 (70.9%)ABSTAIN: 2,291,117 (29.1%)

Largest asset managers voting on “To elect three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their ” at COHERUS BIOSCIENCES INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	3,202,385	0	For
Charles Schwab	0	986,197	Abstain
Delaware/Macquarie	900,000	0	For
SEI	0	857,296	Abstain
BlackRock	525,254	105,554	For
Equitable	22,008	188,410	Abstain
Fidelity	177,047	0	For
BRIDGEWAY FUNDS INC	91,117	0	For
Lincoln Financial	83,905	0	For
WisdomTree	80,178	0	For
Global X	0	67,376	Abstain
Goldman Sachs	66,033	0	For
Northern Trust	63,724	0	For
AQR	62,143	0	For
AIG/SunAmerica	58,876	0	For
Pacific Life	50,901	0	For
QUANTITATIVE MASTER SERIES LLC	46,319	0	For
Bridge Builder Trust	41,829	0	For
MASTER INVESTMENT PORTFOLIO	0	34,806	Abstain
Voya	33,119	0	For
Brighthouse	0	29,534	Abstain
John Hancock	29,316	0	For
DWS	17,544	0	For
Calvert	0	9,819	Abstain
ProShares	7,748	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

3. To elect three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Jill O'Donnell-Tormey, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-11.

Combines 4 wordings of this item as funds reported it.

84% Majority: yes · of votes cast

FOR 84%WITHHELD 16%

FOR: 32,769,503WITHHELD: 6,158,468

COHERUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Jill O'Donnell-Tormey, Ph.D.”): 32,769,503 for, 6,158,468 withheld, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 114,725,740 outstanding shares: 29% for, 5% withheld (34% of the company cast a for/withheld vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (7,644,699 for, 0 against).

FOR 97%

FOR: 7,644,699 (97.1%)ABSTAIN: 227,763 (2.9%)

Largest asset managers voting on “To elect three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their ” at COHERUS BIOSCIENCES INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	3,202,385	0	For
Charles Schwab	986,197	0	For
Delaware/Macquarie	900,000	0	For
SEI	857,296	0	For
BlackRock	630,808	0	For
Equitable	22,008	188,410	Abstain
Fidelity	177,047	0	For
BRIDGEWAY FUNDS INC	91,117	0	For
Lincoln Financial	83,905	0	For
WisdomTree	80,178	0	For
Global X	67,376	0	For
Goldman Sachs	66,033	0	For
Northern Trust	63,724	0	For
AQR	62,143	0	For
AIG/SunAmerica	58,876	0	For
Pacific Life	50,901	0	For
QUANTITATIVE MASTER SERIES LLC	46,319	0	For
Bridge Builder Trust	41,829	0	For
MASTER INVESTMENT PORTFOLIO	34,806	0	For
Voya	33,119	0	For
Brighthouse	0	29,534	Abstain
John Hancock	29,316	0	For
DWS	17,544	0	For
Calvert	0	9,819	Abstain
ProShares	7,748	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

4. To elect three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Michael Ryan

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-11.

Combines 3 wordings of this item as funds reported it.

84% Majority: yes · of votes cast

FOR 84%WITHHELD 16%

FOR: 32,735,184WITHHELD: 6,192,787

COHERUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Michael Ryan”): 32,735,184 for, 6,192,787 withheld, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 114,725,740 outstanding shares: 29% for, 5% withheld (34% of the company cast a for/withheld vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (7,643,767 for, 0 against).

FOR 97%

FOR: 7,643,767 (97.1%)ABSTAIN: 228,695 (2.9%)

Largest asset managers voting on “To elect three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their ” at COHERUS BIOSCIENCES INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	3,202,385	0	For
Charles Schwab	986,197	0	For
Delaware/Macquarie	900,000	0	For
SEI	857,296	0	For
BlackRock	630,808	0	For
Equitable	22,008	188,410	Abstain
Fidelity	177,047	0	For
BRIDGEWAY FUNDS INC	91,117	0	For
Lincoln Financial	83,905	0	For
WisdomTree	80,178	0	For
Global X	67,376	0	For
Goldman Sachs	66,033	0	For
Northern Trust	63,724	0	For
AQR	62,143	0	For
AIG/SunAmerica	58,876	0	For
Pacific Life	50,901	0	For
QUANTITATIVE MASTER SERIES LLC	46,319	0	For
Bridge Builder Trust	41,829	0	For
MASTER INVESTMENT PORTFOLIO	34,806	0	For
Voya	33,119	0	For
Brighthouse	0	29,534	Abstain
John Hancock	29,316	0	For
DWS	17,544	0	For
Calvert	0	9,819	Abstain
ProShares	7,748	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

5. To approve the amendment to the Company's 2014 Employee Stock Purchase Plan (the "ESPP Amendment").

COMPENSATIONMajority of the votes cast: yes

Meeting held 2025-06-11.

Combines 3 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%AGAINST 21%

FOR: 27,741,397AGAINST: 7,585,461

COHERUS BIOSCIENCES INC.’s own tally for this item (“Proposal 4. The Company's stockholders approved the amendment to the Company's 2014 Employee Stock Purchase Plan (the "ESPP Amendment").”): 27,741,397 for, 7,585,461 against, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 114,725,740 outstanding shares: 24% for, 7% against (31% of the company cast a for/against vote).

The 37 asset managers below cast 99.6% of the shares they voted on this item FOR (7,842,928 for, 29,534 against).

FOR 99.6%

FOR: 7,842,928 (99.6%)AGAINST: 29,534 (0.4%)

Largest asset managers voting on “To approve the amendment to the Company's 2014 Employee Stock Purchase Plan (the "ESPP Amendment").” at COHERUS BIOSCIENCES INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	3,202,385	0	For
Charles Schwab	986,197	0	For
Delaware/Macquarie	900,000	0	For
SEI	857,296	0	For
BlackRock	630,808	0	For
Equitable	210,418	0	For
Fidelity	177,047	0	For
BRIDGEWAY FUNDS INC	91,117	0	For
Lincoln Financial	83,905	0	For
WisdomTree	80,178	0	For
Global X	67,376	0	For
Goldman Sachs	66,033	0	For
Northern Trust	63,724	0	For
AQR	62,143	0	For
AIG/SunAmerica	58,876	0	For
Pacific Life	50,901	0	For
QUANTITATIVE MASTER SERIES LLC	46,319	0	For
Bridge Builder Trust	41,829	0	For
MASTER INVESTMENT PORTFOLIO	34,806	0	For
Voya	33,119	0	For
Brighthouse	0	29,534	Against
John Hancock	29,316	0	For
DWS	17,544	0	For
Calvert	9,819	0	For
ProShares	7,748	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

6. TO RATIFY THE SELECTION, BY THE AUDIT COMMITTEE OF OUR BOARD OF DIRECTORS, OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2025-06-11.

99% Majority: yes · of votes cast

FOR 99%

FOR: 74,500,950AGAINST: 776,953

COHERUS BIOSCIENCES INC.’s own tally for this item (“Proposal 2. The Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.”): 74,500,950 for, 776,953 against, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 114,725,740 outstanding shares: 65% for, 0.7% against (66% of the company cast a for/against vote).

The 37 asset managers below cast 99.9% of the shares they voted on this item FOR (7,841,996 for, 932 against).

FOR 99.6%

FOR: 7,841,996 (99.6%)AGAINST: 932 (0.0%)ABSTAIN: 29,534 (0.4%)

Largest asset managers voting on “TO RATIFY THE SELECTION, BY THE AUDIT COMMITTEE OF OUR BOARD OF DIRECTORS, OF ERNST & YOUNG LLP AS OUR INDEPEN” at COHERUS BIOSCIENCES INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	3,202,385	0	For
Charles Schwab	986,197	0	For
Delaware/Macquarie	900,000	0	For
SEI	857,296	0	For
BlackRock	630,808	0	For
Equitable	210,418	0	For
Fidelity	177,047	0	For
BRIDGEWAY FUNDS INC	91,117	0	For
Lincoln Financial	83,905	0	For
WisdomTree	80,178	0	For
Global X	67,376	0	For
Goldman Sachs	66,033	0	For
Northern Trust	63,724	0	For
AQR	62,143	0	For
AIG/SunAmerica	58,876	0	For
Pacific Life	50,901	0	For
QUANTITATIVE MASTER SERIES LLC	46,319	0	For
Bridge Builder Trust	41,829	0	For
MASTER INVESTMENT PORTFOLIO	34,806	0	For
Voya	33,119	0	For
Brighthouse	0	29,534	Abstain
John Hancock	29,316	0	For
DWS	17,544	0	For
Calvert	9,819	0	For
ProShares	7,748	0	For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

7. TO APPROVE THE TRANSACTION, THE ASSET PURCHASE AGREEMENT AND THE OTHER TRANSACTIONS AND ANCILLARY DOCUMENTS CONTEMPLATED BY THE ASSET PURCHASE AGREEMENT.

EXTRAORDINARY TRANSACTIONS

Meeting held 2025-03-11; no official results are on file for this meeting.

100% fund support · no official result

FOR 100%

The 36 asset managers below cast 100% of the shares they voted on this item FOR (14,969,533 for, 0 against).

FOR: 14,969,533 (100.0%)

Largest asset managers voting on “TO APPROVE THE TRANSACTION, THE ASSET PURCHASE AGREEMENT AND THE OTHER TRANSACTIONS AND ANCILLARY DOCUMENTS CO” at COHERUS BIOSCIENCES INC., 2024-2025
Asset manager	For	Vote
Vanguard	10,761,099	For
SEI	1,024,136	For
Delaware/Macquarie	900,000	For
Charles Schwab	689,973	For
BlackRock	635,979	For
Equitable	236,071	For
Fidelity	121,665	For
Lincoln Financial	83,905	For
Northern Trust	63,724	For
AQR	62,143	For
BRIDGEWAY FUNDS INC	47,027	For
Pacific Life	46,380	For
Bridge Builder Trust	41,829	For
Voya	34,937	For
MASTER INVESTMENT PORTFOLIO	34,806	For
WisdomTree	30,225	For
Brighthouse	29,535	For
John Hancock	18,983	For
Global X	16,261	For
Victory Capital	13,627	For
AIG/SunAmerica	12,327	For
Nationwide	11,892	For
Goldman Sachs	10,450	For
Calvert	9,819	For
ProShares	8,318	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Largest COHERUS BIOSCIENCES INC. shareholders voting in 2024-2025

Ranked by the number of COHERUS BIOSCIENCES INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 114,725,740 shares outstanding at the time of that meeting.

Top COHERUS BIOSCIENCES INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Vanguard	2.90%
2	BlackRock	2.40%
3	Rubric Capital Management LP	2.22%
4	Kohlberg Kravis Roberts & Co. L.P.	1.79%
5	Charles Schwab	1.72%
6	C WorldWide Asset Management Fondsmaeglerselskab A/S	1.68%
7	SEI	1.49%
8	State Street	0.94%
9	Delaware/Macquarie	0.78%
10	MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	0.78%

Reported COHERUS BIOSCIENCES INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

COHERUS BIOSCIENCES INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Vanguard Group	9.72%	13F
BlackRock	9.57%	13F
Evgeny Zaytsev ("Zaytsev")	6.63%	13G
Thomas A. Satterfield, Jr.	6.04%	13G
Ali J. Satvat	2.65%	DEF14A
Millennium Management	2.53%	13F
State Street	1.94%	13F
Dennis M. Lanfear	1.05%	DEF14A
Northern Trust	0.83%	13F
Goldman Sachs	0.48%	13F

Percentages above are of 114,725,740 shares outstanding, as reported by COHERUS BIOSCIENCES INC. on its Form 10-Q dated 2024-04-30 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from COHERUS BIOSCIENCES INC.’s 10-Q dated 2024-04-30. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At COHERUS BIOSCIENCES INC.'s 2 shareholder meetings in the 2024-2025 proxy season (held 2025-03-11 and 2025-06-11), 118 asset managers reported how they voted in their SEC Form N-PX filings, covering 858 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item of the season, voted at the meeting held 2025-06-11 — To vote on a non-binding, advisory basis to approve the compensation of the Company's named… — FOR was 54.3% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: COHERUS BIOSCIENCES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-13.

COHERUS BIOSCIENCES INC. proxy season coverage: 2023-2024 · 2024-2025 (this page).